NASDAQ:XAIR - US08862L1035 - Common Stock
The current stock price of XAIR is 2.2 USD. In the past month the price decreased by -22.38%. In the past year, price decreased by -74.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.79 | 228.46B | ||
ISRG | INTUITIVE SURGICAL INC | 57.8 | 166.80B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.51 | 157.29B | ||
SYK | STRYKER CORP | 30.24 | 148.57B | ||
MDT | MEDTRONIC PLC | 16.93 | 120.10B | ||
BDX | BECTON DICKINSON AND CO | 13.24 | 54.14B | ||
IDXX | IDEXX LABORATORIES INC | 53.08 | 51.00B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.74 | 47.88B | ||
RMD | RESMED INC | 28.36 | 39.65B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.61B | ||
DXCM | DEXCOM INC | 43.66 | 29.11B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.98 | 26.00B |
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
BEYOND AIR INC
900 Stewart Ave, Suite 301
Garden City NEW YORK 11530 US
CEO: Steven Lisi
Employees: 107
Phone: 15166658200
The current stock price of XAIR is 2.2 USD. The price decreased by -0.9% in the last trading session.
The exchange symbol of BEYOND AIR INC is XAIR and it is listed on the Nasdaq exchange.
XAIR stock is listed on the Nasdaq exchange.
12 analysts have analysed XAIR and the average price target is 11.42 USD. This implies a price increase of 419.27% is expected in the next year compared to the current price of 2.2. Check the BEYOND AIR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BEYOND AIR INC (XAIR) has a market capitalization of 11.51M USD. This makes XAIR a Nano Cap stock.
BEYOND AIR INC (XAIR) currently has 107 employees.
BEYOND AIR INC (XAIR) has a resistance level at 2.29. Check the full technical report for a detailed analysis of XAIR support and resistance levels.
The Revenue of BEYOND AIR INC (XAIR) is expected to grow by 238.81% in the next year. Check the estimates tab for more information on the XAIR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XAIR does not pay a dividend.
BEYOND AIR INC (XAIR) will report earnings on 2025-11-10.
BEYOND AIR INC (XAIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.61).
The outstanding short interest for BEYOND AIR INC (XAIR) is 9.78% of its float. Check the ownership tab for more information on the XAIR short interest.
ChartMill assigns a fundamental rating of 3 / 10 to XAIR. XAIR has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months XAIR reported a non-GAAP Earnings per Share(EPS) of -6.61. The EPS decreased by -303.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -149.8% | ||
ROE | -424.25% | ||
Debt/Equity | 0.97 |
12 analysts have analysed XAIR and the average price target is 11.42 USD. This implies a price increase of 419.27% is expected in the next year compared to the current price of 2.2.
For the next year, analysts expect an EPS growth of 18.45% and a revenue growth 238.81% for XAIR